Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial
Tóm tắt
Cancer patients often experience diminished cognitive function (CF) and quality of life (QOL) due to the side effects of treatment and the disease symptoms. This study evaluates the effects of medical Qigong (MQ; combination of gentle exercise and meditation) on CF, QOL, and inflammation in cancer patients. Eighty-one cancer patients recruited between October 2007 and May 2008 were randomly assigned to two groups: a control group (n = 44) who received the usual health care and an intervention group (n = 37) who participated in a 10-week MQ program. Self-reported CF was measured by the European Organization for Research and Treatment of Cancer (EORTC-CF) and the Functional Assessment of Cancer Therapy—Cognitive (FACT-Cog). The Functional Assessment of Cancer Therapy—General (FACT-G) was used to measure QOL. C-reactive protein (CRP) was assessed as a biomarker of inflammation. The MQ group self-reported significantly improved CF (mean difference (MD) = 7.78, t
51 = −2.532, p = 0.014) in the EORTC-CF and all the FACT-Cog subscales [perceived cognitive impairment (MD = 4.70, t
43 = −2.254, p = 0.029), impact of perceived cognitive impairment on QOL (MD = 1.64, t
45 = −2.377, p = 0.024), and perceived cognitive abilities (MD = 3.61, t
45 = −2.229, p = 0.031)] compared to controls. The MQ group also reported significantly improved QOL (MD = 12.66, t
45 = −5.715, p < 0.001) and had reduced CRP levels (MD = −0.72, t
45 = 2.092, p = 0.042) compared to controls. Results suggest that MQ benefits cancer patients’ self-reported CF, QOL, and inflammation. A larger randomized controlled trial including an objective assessment of CF is planned.
Tài liệu tham khảo
Vardy J, Wefel JS, Ahles T et al (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 19(4):623–629
Jenkins V (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834
Shilling V, Jenkins V (2007) Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11(1):6–15
Boykoff N, Moieni M, Subramanian S (2009) Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3(4):223–232
Vardy J, Rourke S, Tannock I (2007) Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 25(17):2455
Schagen SB (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650
van Dam FS (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218
Castellon SA (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955–969
Ahles TA (2002) Neuropsychological impact of standard-dose chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493
Vardy J, Xu W, Booth C et al (2008) Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer. ASCO Meeting Abstracts, p 9520
Schagen SB, Muller MJ, Boogerd W et al (2006) Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98(23):1742–1745
Wefel J, Lenzi R, Theriault R et al (2004) Chemobrain in breast carcinoma? A prologue. Cancer 101(3):466–475
Von Ah D, Harvison KW, Monahan PO et al (2009) Cognitive function in breast cancer survivors compared to healthy age- and education-matched women. Clin Neuropsychol 23(4):661–674
Fan HGM, Houede-Tchen N, Yi Q-L et al (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23(31):8025–8032
Vardy J (2009) Cognitive function in survivors of cancer. ASCO Educational Book 2009(1):570–574
Roberts RO, Geda YE, Knopman DS et al (2010) Metabolic syndrome, inflammation, and nonamnestic mild cognitive impairment in older persons: a population-based study. Alzheimer Dis Assoc Disord 24(1):11–18. doi:10.1097/WAD.0b013e3181a4485c
Seruga B, Zhang H, Bernstein L et al (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8(11):887–899
Onem Y, Terekeci H, Kucukardali Y et al (2010) Albumin, hemoglobin, body mass index, cognitive and functional performance in elderly persons living in nursing homes. Arch Gerontol Geriatr 50(1):56–59
Seeman TE, McEwen BS, Singer BH et al (1997) Increase in urinary cortisol excretion and memory declines: MacArthur studies of successful aging. J Clin Endocrinol Metab 82(8):2458–2465
Jim H, Small B, Patterson S et al (2010) Cognitive impairment in men treated with luteinizing hormone-releasing hormone agonists for prostate cancer: a controlled comparison. Supportive Care Cancer 18(1):21–27. doi:10.1007/s00520-009-0625-3
Ahles TA, Saykin AJ, Noll WW et al (2003) The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12(6):612–619
Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7(3):192–201
Silverman D, Dy C, Castellon S et al (2007) Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat 103(3):303–311
Oh B, Butow P, Mullan B et al (2009) Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Ann Oncol 21:608–614
Kemoun G, Thibaud M, Roumagne N et al (2010) Effects of a physical training programme on cognitive function and walking efficiency in elderly persons with dementia. Dement Geriatr Cogn Disord 29(2):109–114
Etnier J, Johnston R, Dagenbach D et al (1999) The relationships among pulmonary function, aerobic fitness, and cognitive functioning in older COPD patients*. Chest 116(4):953–960
Colcombe AM, Kramer AF, Irwin DE et al (2003) Age-related effects of attentional and oculomotor capture by onsets and color singletons as a function of experience. Acta Psychologica 113(2):205–225
Lautenschlager NT, Cox KL, Flicker L et al (2008) Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 300(9):1027–1037
Heikkila K, Ebrahim S, Rumley A et al (2007) Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women’s Heart and Health Study. Cancer Epidemiol Biomarkers Prev 16(6):1155–1159
Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
Jacobs SR, Jacobsen PB, Booth-Jones M et al (2007) Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoetic stem cell transplant patients. J Pain Symptom Manag 33(1):13–23
Wagner L, Sweet J, Butt Z et al (2009) Measuring patient self-reported cognitive function: development of the Functional Assessment of Cancer Therapy—Cognitive Function instrument. J Support Oncol 7(6):W32–W39
Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579
Hwang SS, Chang VT, Kasimis BS et al (2003) A comparison of three fatigue measures in veterans with cancer. Cancer Investigation 21(3):363–373
Carlson LE, Speca M, Patel KD et al (2004) Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology 29(4):448–474
Mutrie N, Campbell AM, Whyte F et al (2007) Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. BMJ 334(7592):517
Pierce BL, Ballard-Barbash R, Bernstein L et al (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27(21):3437–3444
Noble JM, Manly JJ, Schupf N et al (2010) Association of C-reactive protein with cognitive impairment. Arch Neurol 67(1):87–92
Yeh M, Lee T, Chen H et al (2006) The influences of Chan-Chuang Qi-gong therapy on complete blood cell counts in breast cancer patients treated with chemotherapy. Cancer Nurs 29(2):149–155
Luo S, Tong T (1988) Effect of vital gate Qigong exercise on malignant tumor. First World Conference for Academic Exchange of Medical Qigong, Beijing, p 122